Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2156 studies found for:    myeloma
Show Display Options
Rank Status Study
1 Active, not recruiting Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: aMILs;   Biological: Allogeneic Myeloma Vaccine
2 Completed Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America
Conditions: Multiple Myeloma;   Leukemia;   Lymphoid;   Lymphoma;   Non-Hodgkin
Interventions: Other: Chronic Lymphocytic Leukemia (CLL);   Other: Multiple Myeloma (MM);   Other: Non-Hodgkin's lymphoma (NHL)
3 Recruiting Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Condition: Multiple Myeloma
Interventions: Procedure: Tumor Cell Collection;   Procedure: Autologous Stem Cell Transplant;   Drug: Melphalan;   Procedure: Leukapheresis;   Biological: Myeloma vaccine;   Drug: GM-CSF;   Drug: Lenalidomide
4 Active, not recruiting Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Condition: Multiple Myeloma
Intervention:
5 Completed
Has Results
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Myeloma Immunoglobulin Idiotype Vaccine;   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine Sulfate;   Drug: Methotrexate;   Biological: GMCSF (granulocyte macrophage colony stimulating factor);   Biological: GCSF (granulocyte colony stimulating factor)
6 Recruiting Role of Osteocytes in Myeloma Bone Disease
Condition: Multiple Myeloma
Intervention:
7 Unknown  Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Condition: Multiple Myeloma
Intervention:
8 Recruiting Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma;   Infection
Interventions: Drug: Standard myeloma treatment;   Drug: Clarithromycin;   Drug: Sulfamethoxazole/trimethoprim;   Drug: Observation
9 Active, not recruiting A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance
Condition: Multiple Myeloma
Intervention: Other: Anti-myeloma treatment at physician discretion
10 Recruiting A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Condition: Multiple Myeloma
Interventions: Drug: Revlimid;   Drug: Velcade;   Drug: dexamethasone;   Drug: Farydak
11 Recruiting An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients
Condition: Multiple Myeloma
Intervention: Other: No Intervention
12 Terminated
Has Results
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
13 Completed Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Conditions: Graft vs Host Disease;   Multiple Myeloma
Interventions: Drug: Myeloma Immunoglobulin Idiotype Vaccine-KLH;   Drug: GM-CSF
14 Active, not recruiting Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Fludarabine
15 Recruiting Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies
Conditions: Monoclonal Gammopathy of Unknown Significance;   Smoldering Multiple Myeloma
Intervention: Procedure: Blood Collection
16 Active, not recruiting Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Biological: Allogeneic Myeloma Vaccine;   Biological: Prevnar-13
17 Completed Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
18 Terminated
Has Results
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Conditions: Cancer;   Myeloma;   Multiple Myeloma
Intervention: Drug: Bortezomib
19 Completed Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib
20 Completed Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: CC-5013

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years